StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)

Close on Nov 17, 2026Market cap $15.86BP/E –Yield –

Charles River Laboratories International ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Charles River Laboratories International's ebitda for the twelve months ending Jun 27, 2026 was $388.03M, down 30.0% year over year. For fiscal 2025 it was $428.47M, down 27.3% from the year before. Over ten years it grew 3.6% a year on average. The highest annual figure on record is $954.85M in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 27, 2025$428.47M-27.3%
FY2024Dec 28, 2024$589.09M-36.8%
FY2023Dec 30, 2023$931.39M-2.5%
FY2022Dec 31, 2022$954.85M+11.6%
FY2021Dec 25, 2021$855.40M+28.1%
FY2020Dec 26, 2020$667.65M+21.6%
FY2019Dec 28, 2019$549.25M+11.4%
FY2018Dec 29, 2018$493.16M+17.6%
FY2017Dec 30, 2017$419.44M+15.2%
FY2016Dec 31, 2016$364.21M+20.9%
FY2015Dec 26, 2015$301.33M+9.9%
FY2014Dec 27, 2014$274.12M+10.5%
FY2013Dec 28, 2013$248.04M+0.4%
FY2012Dec 29, 2012$247.04M-4.8%
FY2011Dec 31, 2011$259.54M–
FY2010Dec 25, 2010-$204.86M-178.9%
FY2009Dec 26, 2009$259.58M–
FY2008Dec 27, 2008-$364.99M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$187.18M-14.8%
Q1 FY2026Mar 28, 2026$187.05M-4.1%
Q4 FY2025Dec 27, 2025-$205.16M–
Q3 FY2025Sep 27, 2025$218.96M+6.5%
Q2 FY2025Jun 28, 2025$219.64M-7.6%
Q1 FY2025Mar 29, 2025$195.03M-7.7%
Q4 FY2024Dec 28, 2024-$65.58M-130.7%
Q3 FY2024Sep 28, 2024$205.60M-10.8%
Q2 FY2024Jun 29, 2024$237.73M-2.0%
Q1 FY2024Mar 30, 2024$211.33M-13.7%
Q4 FY2023Dec 30, 2023$213.44M-11.6%
Q3 FY2023Sep 30, 2023$230.37M+2.1%
Q2 FY2023Jul 1, 2023$242.62M-8.0%
Q1 FY2023Apr 1, 2023$244.96M+9.3%
Q4 FY2022Dec 31, 2022$241.36M+0.5%
Q3 FY2022Sep 24, 2022$225.58M+0.5%
Q2 FY2022Jun 25, 2022$263.83M+28.3%
Q1 FY2022Mar 26, 2022$224.08M+21.0%
Q4 FY2021Dec 25, 2021$240.05M+26.5%
Q3 FY2021Sep 25, 2021$224.49M+16.7%
Q2 FY2021Jun 26, 2021$205.66M+53.5%
Q1 FY2021Mar 27, 2021$185.21M+22.2%
Q4 FY2020Dec 26, 2020$189.80M+18.2%
Q3 FY2020Sep 26, 2020$192.33M+33.0%
Q2 FY2020Jun 27, 2020$133.98M+3.9%
Q1 FY2020Mar 28, 2020$151.54M+31.6%
Q4 FY2019Dec 28, 2019$160.62M+11.5%
Q3 FY2019Sep 28, 2019$144.56M+13.0%
Q2 FY2019Jun 29, 2019$128.91M+7.3%
Q1 FY2019Mar 30, 2019$115.15M+14.0%
Q4 FY2018Dec 29, 2018$144.06M+49.6%
Q3 FY2018Sep 29, 2018$127.95M+19.0%
Q2 FY2018Jun 30, 2018$120.11M+5.8%
Q1 FY2018Mar 31, 2018$101.04M-1.1%
Q4 FY2017Dec 30, 2017$96.31M-8.0%
Q3 FY2017Sep 30, 2017$107.53M+15.7%
Q2 FY2017Jul 1, 2017$113.49M–
Q1 FY2017Apr 1, 2017$102.12M–
Q4 FY2016Dec 31, 2016$104.63M–
Q3 FY2016Sep 24, 2016$92.90M–

More Charles River Laboratories International figures

See a number that looks wrong?